Navigation Links
TissueGene Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis
Date:11/14/2012

ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- TissueGene, Inc. announced today that it has completed patient enrollment for a U.S. Phase II clinical trial of TG-C in patients suffering from severe osteoarthritis of the knee.  TG-C is a therapy that involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 to regenerate cartilage.

The randomized, double-blind, placebo-controlled study has been designed to evaluate the safety and efficacy of TG-C in patients with Grade 3 chronic degenerative joint disease (DJD) of the knee.  This multi-center study has been conducted at five hospitals and clinical research centers across the country specializing in orthopedics.  Patients have received an intra-articular injection of either TG-C or placebo to the damaged joint area.  Patients in this study are being followed for two years with the primary efficacy endpoint analysis being conducted once all patients have reached their one year follow-up.  In conjunction with this milestone, TissueGene's licensing partner, Kolon Life Science, Inc. has completed patient enrollment for a Phase IIb study of TG -C in Korea.  

"We are very pleased with the clinical progress of TG-C in both the US and Korea and look forward to reporting our Phase II data in 2013," stated Dr. Kwan Hee Lee, Chief Medical Officer of TissueGene.

About TissueGene, Inc.

TissueGene, Inc. is a Maryland-based biopharmaceutical company focused on developing novel regenerative therapies for the treatment of various orthopedic diseases.  TissueGene's proprietary technology employs a form of cell-mediated therapy to deliver therapeutic proteins to localized areas of damaged tissue.  The company is currently developing four product candidates for the regeneration of cartilage (TG-C), bone (TG-B), disc (TG-D), and nerve tissue (TG-N).  For more information, please visit http://www.TissueGene.com.

About Kolon Life Science, Inc.

Kolon Life Science, Inc. (KOSDAQ: 102940), a subsidiary company of Kolon Group, is a leading Korean-based biochemical company focused on pharmaceutical ingredients and environmental biochemicals.  Its pharmaceutical business division provides active pharmaceutical ingredients and pharmaceutical intermediates ranging from zaltoprofen and flurbiprofen to argatroban and voglibose.  For more information, please visit http://www.kolonls.co.kr.


'/>"/>
SOURCE TissueGene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
4. CryoLife Completes Acquisition of Hemosphere
5. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
8. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
9. Ablative Solutions Completes $5.3M Series A Financing
10. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
11. Spine Pain Management, Inc. Completes $500,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016 Noom, Inc., ... it will charge enterprise customers only when their members ... the health and wellness sector, which typically charges for ... - http://photos.prnewswire.com/prnh/20161207/446824LOGO ... the power of technology with the empathy of live ...
(Date:12/8/2016)... , Dec. 8, 2016 Augmedix, ... announced that it has closed a $23 million ... Ventures and OrbiMed. The company seeks to rehumanize ... physicians spend on mandated EHR documentation. The Augmedix ... service that frees doctors from 3 hours of ...
(Date:12/8/2016)... N.Y. , Dec. 8, 2016 Henry Schein, ... of health care products and services to office-based dental, animal ... 80 percent equity investment in Marrodent, one of ... of approximately $32 million. This transaction was announced on August ... customers in Poland since 2014, and ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Silhouette Instalift ... lines by smoothing and tightening the skin of the face to create more ... facial aging with very little downtime, Silhouette Instalift is a novel, minimally invasive ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... up with a schizophrenic mother in a unique, personal perspective through animation. ... treating trauma and addictive disorders at her private psychotherapy practice. Sheri’s mother, Pearl, ...
(Date:12/7/2016)... ... December 07, 2016 , ... In the early morning of ... an emergency medical call when he lost control of his patrol car. The vehicle ... his vehicle, he was transported to Atlanta Medical Center, where he later succumbed to ...
(Date:12/7/2016)... ... December 07, 2016 , ... Castle Dermatology Institute is now ... to restore a more youthful appearance to the face. Dr. Peyman Ghasri and Dr. ... a variety of other treatments, to rejuvenate and renew the facial appearance. , ...
(Date:12/7/2016)... Ill. (PRWEB) , ... December 07, 2016 , ... Levels ... early-stage brain damage, according to a study appearing online in the journal Radiology. , ... is expected to increase significantly due to the rapidly aging population. Damage to both ...
Breaking Medicine News(10 mins):